Eli Lilly’s Lyumjev (insulin lispro-aabc injection) Receives the US FDA’s Expanded Label Approval for the Treatment of Type 1 and Type 2 Diabetes

August 17, 2021 Auto Bot Eli Lilly, FDA, regulatory 0

Shots:

  • The approval is based on P-III PRONTO-PUMP-2, a treat-to-target study that evaluates the efficacy & safety of Lyumjev (insulin lispro-aabc injection, 100 units/mL) vs Humalog (insulin lispro injection, 100 units/mL) in 432 adults in a ratio (1:1) with T1D for 16wks.
  • The study met its 1EPs i.e., non-inferior A1C reduction from baseline @16wks. Lyumjev demonstrated a superior reduction in blood glucose spikes at 1hr. & 2hrs. after a test meal
  • Lyumjev is also approved in Japan & EU. Additionally, the Lilly insulin value program is available for patients with commercial insurance or no insurance along with a Seniors Savings model for people in a Medicare Part D program

Click here to­ read full press release/ article | Ref: Eli Lilly | Image: Forbes

The post Eli Lilly’s Lyumjev (insulin lispro-aabc injection) Receives the US FDA’s Expanded Label Approval for the Treatment of Type 1 and Type 2 Diabetes first appeared on PharmaShots.